iTeos hlt Vortrag auf der 43. jhrlichen J.P. Morgan Healthcare Conference
| ITOS Stock | USD 7.64 0.03 0.39% |
Slightly above 61% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Iteos |
WATERTOWN, Massachusetts, und GOSSELIES, Jan. 08, 2025 -- iTeos Therapeutics, Inc. , ein im klinischen Stadium ttiges...
Read at globenewswire.com
 |
Iteos Therapeutics Fundamental Analysis
We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Iteos Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Iteos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.
Peers
Iteos Therapeutics Related Equities
| AMLX | Amylyx Pharmaceuticals | 1.12 | ||||
| DAWN | Day One | 1.05 | ||||
| GLUE | Monte Rosa | 0.36 | ||||
| KYMR | Kymera Therapeutics | 0.29 | ||||
| RVMD | Revolution Medicines | 0.36 | ||||
| MLTX | MoonLake Immunotherapeuti | 0.49 | ||||
| BPMC | Blueprint Medicines | 0.62 | ||||
| ABOS | Acumen Pharmaceuticals | 1.14 | ||||
| TCRX | Tscan Therapeutics | 1.56 | ||||
| ERAS | Erasca | 2.01 | ||||
| APLS | Apellis Pharmaceuticals | 2.47 | ||||
| ANNX | Annexon | 2.59 | ||||
| DSGN | Design Therapeutics | 2.93 | ||||
| TERN | Terns Pharmaceuticals | 3.02 | ||||
| SANA | Sana Biotechnology | 3.15 |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.